tirzepatide removed from shortage list FDA confirms is still over, gives compounders a grace period Minus one of its GLP-1

Seems like everybody and their mother is on Ozempic, Rybelsus, or Wygovy these days for weight loss

A major trial, the EMPA-REG Outcome study, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes enrolled patients with type 2 diabetes who were also at high risk of cardiovascular events such as strokes or heart attacks to take Empagliflozin and monitor if there were any beneficial effects in this group

doi: 10.1006/bbrc.2000.4065

Integrative and functional nutrition care plan

Additionally, tirzepatidea dual GIP/GLP-1 receptor agonistdemonstrated substantial efficacy in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis

Be vigilant for signs of hypoglycemia and have a plan for quickly raising your blood sugar